PF-Atlas › Treatments › LNP-mRNA Lung-Targeted Gene Delivery
LNP-mRNA Lung-Targeted Gene Delivery
Lipid nanoparticle platform delivers therapeutic mRNA specifically to lung epithelium
Clinical research — In human clinical trials (Phase I–III). How PF-Atlas grades evidence.
Development stage
Phase I (multiple)
Evidence level
Level 2 (Platform)
Mechanism class
Lipid nanoparticle platform delivers therapeutic mRNA specifically to lung epithelium
Timeline
2-4 years
Risk profile
Low-Medium
Developer
UT Southwestern / UCLA
Key researchers
D. Siegwart
Overview
SORT LNP technology enables organ-specific delivery. UCLA Feb 2026: full CFTR gene delivered to human airway cells via LNP. Platform technology applicable to any therapeutic gene — TERT, anti-fibrotic cytokines, reprogramming factors. Enables inhaled gene therapy without viral vectors.
How LNP-mRNA Lung-Targeted Gene Delivery fits into IPF treatment
LNP-mRNA Lung-Targeted Gene Delivery is classified as Level 2 (Platform) at the Phase I (multiple) stage. Explore how it compares to other options and where it sits in the development pipeline:
Other IPF treatments
Medical disclaimer. This page summarizes published research and PF-Atlas model output about LNP-mRNA Lung-Targeted Gene Delivery for information only. It is not medical advice or a treatment recommendation. Drug availability, approval status and evidence change — verify with a pulmonologist and official sources (FDA, ClinicalTrials.gov) before any decision.